- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on HER2-PositiveRecurrent or Metastatic Breast Cancer in United States
Total 1351 results
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
-
QuantumLeap Healthcare CollaborativeByondis B.V.WithdrawnOvarian Cancer | Metastatic Cancer | Metastatic Breast Cancer | Bladder Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Gastroesophageal Adenocarcinoma | Ovarian Carcinoma | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoid Tumor | HER2-positive Metastatic Breast... and other conditionsUnited States
-
Pravin T.P KaumayaNot yet recruitingMetastatic Breast Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastrointestinal Carcinoma | EGFR OverexpressionUnited States
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)RecruitingHER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of BreastUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)Not yet recruitingMetastatic Breast Cancer | Estrogen-receptor-positive Breast Cancer | HER2/Neu-Negative Breast Cancer | Advanced Breast CancervUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteTerminatedBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein OverexpressionUnited States
-
Seagen Inc.CompletedHER2 Positive Metastatic Breast CancersUnited States
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
-
Saint Luke's Health SystemNovartis PharmaceuticalsRecruitingMetastatic Breast Cancer | HER2-negative Breast CancerUnited States
-
University of California, IrvineRecruitingBreast Cancer | Metastatic Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerUnited States
-
Nancy Lin, MDGenentech, Inc.Active, not recruitingHER2-positive Metastatic Breast Cancer | Central Nervous System MetastasesUnited States
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
University of MiamiRecruitingBreast Cancer | Metastatic Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
University of MiamiRecruitingStage IV Breast Cancer | HER2-positive Metastatic Breast CancerUnited States
-
University of Wisconsin, MadisonRecruitingBreast Cancer | Metastatic Breast Cancer | HER2-negative Breast CancerUnited States
-
Orum Therapeutics USA, Inc.RecruitingHER2-positive Breast Cancer | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein OverexpressionUnited States
-
Polaris GroupCompletedHER2 Negative Metastatic Breast CancerUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.; Eisai Inc.TerminatedMetastatic Breast Cancer | HER2-positive Breast CancerUnited States
-
Mayo ClinicRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | Hormone-receptor-positive Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterHoffmann-La Roche; Genentech, Inc.; Hartford HealthCareActive, not recruitingMetastatic HER2-Positive Breast CancerUnited States
-
University of Kansas Medical CenterPfizerTerminatedHER2-positive Breast Cancer | Breast Cancer MetastaticUnited States
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Kimberly BlackwellTerminatedHER2 Positive Untreated Metastatic Breast Cancer | Asymptomatic or Low Symptomatic Brain Metastasis in Breast CancerUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2/Neu-positive Breast CancerUnited States
-
Sponsor GmbHGlaxoSmithKline; iOMEDICO AG; Arbeitsgemeinschaft fur Internistische Onkologie; Arbeitskreis Klinische StudienTerminatedMetastatic Breast Cancer | HER2 Positive | First or Second Line Therapy | Failure or Contraindication of Trastuzumab TherapyGermany
-
National Cancer Institute (NCI)TerminatedBreast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Negative Breast Cancer | HER2+ Breast CancerUnited States
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Criterium, Inc.Novartis; Seagen Inc.RecruitingHER2-positive Metastatic Breast CancerUnited States
-
Bolt Biotherapeutics, Inc.Hoffmann-La RocheActive, not recruitingMetastatic Breast Cancer | HER2-positive Breast CancerSpain, United States, Italy
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Dana-Farber Cancer InstituteJohns Hopkins University; Translational Breast Cancer Research ConsortiumNot yet recruitingBreast Cancer | HER2-positive Breast Cancer | Stage IV Breast Cancer | Breast Cancer Female | Breast Cancer Metastatic | Estrogen Receptor-positive Breast CancerUnited States
-
General Oncology, Inc.Myriad Genetics, Inc.RecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Dana-Farber Cancer InstituteJohns Hopkins University; National Cancer Institute (NCI); Gateway for Cancer... and other collaboratorsRecruitingBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterUnited States Department of DefenseActive, not recruitingBreast Cancer | Metastatic HER2-negative BreastUnited States
-
Dantari, Inc.CompletedHER2-negative Metastatic Breast CancerUnited States
-
Merrimack PharmaceuticalsCompletedMetastatic Breast Cancer | Her2 Amplified Solid TumorsUnited States
-
University of Alabama at BirminghamTesaro, Inc.; Susan G. Komen Breast Cancer Foundation; Translational Breast Cancer... and other collaboratorsRecruitingMetastatic Breast Cancer | HER2 Positive Breast CarcinomaUnited States
-
Genentech, Inc.RecruitingEstrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast CancerKorea, Republic of, United States, Spain, Taiwan, United Kingdom, Japan, Germany, Argentina, Turkey, Greece, Italy, Singapore, South Africa
-
Masonic Cancer Center, University of MinnesotaActive, not recruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | TN ER-/PR-/HER2- Breast Cancer | ERany/PRany/HER2+ Breast CancerUnited States
-
Ana C Garrido-Castro, MDMerck Sharp & Dohme LLC; Gilead SciencesActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | HR-Positive Breast CancerUnited States
-
University of Wisconsin, MadisonContext Therapeutics Inc.TerminatedMetastatic Cancer | ER-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
Clovis Oncology, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | Estrogen Receptor Positive | Triple Negative | HER2 | HER2 Positive | MBC | ERUnited States
-
Infinity Pharmaceuticals, Inc.TerminatedBreast Cancer | Metastatic Breast Cancer | HER2 Positive Breast Cancer | Cancer of the BreastUnited States, Spain
-
University of WashingtonBreast Cancer Research FoundationNot yet recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic HER2-Negative Breast Carcinoma | Metastatic Hormone Receptor-Positive Breast Carcinoma | Locally Advanced Unresectable HER2-Negative Breast Carcinoma | Locally Advanced Unresectable Hormone Receptor-Positive...United States
-
Novartis PharmaceuticalsTerminatedMetastatic Breast Cancer | HER2+ Breast CancerBelgium, France, Spain, United States, United Kingdom, Italy
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
SynDevRx, Inc.RecruitingMetastatic Breast Cancer | HR+/HER2-negative Breast CancerUnited States
-
Imperial College LondonMedical Research Council; ECMCRecruitingMetastatic Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast CancerUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterCompletedBreast Cancer | Metastatic Breast Cancer | Breast Cancer Stage IV | Solid Carcinoma | HER2-negative Breast Cancer | MEK1 Gene Mutation | MEK2 Gene MutationUnited States